Status:
COMPLETED
BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Type 2 diabetes mellitus.
- Managed by diet therapy.
- Must have adequate blood, liver and kidney function.
- Exclusion criteria:
- Serious cardiovascular disease or serious hepatic disease.
Exclusion
Key Trial Info
Start Date :
January 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2007
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00297063
Start Date
January 11 2006
End Date
May 31 2007
Last Update
November 18 2022
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Fukuoka, Japan, 819-0168
2
GSK Investigational Site
Fukushima, Japan, 962-0856
3
GSK Investigational Site
Hokkaido, Japan, 051-0005
4
GSK Investigational Site
Ibaraki, Japan, 311-0113